問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Thoracic Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

更新時間：2023-09-19

孟繁俊
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

26Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

孟繁俊

Tri-Service General Hospital

Division of Thoracic Medicine

List

15Cases

2025-10-01 - 2035-01-20

Active
Beamion LUNG-3: A randomized, controlled, multicenter trial evaluating zongertinib as adjuvant monotherapy versus standard of care in patients with early-stage, resectable non-small cell lung cancer (stage II-IIIB) and HER2 mutations with activated tyrosine kinase domain.

  • Condition/Disease

    DFS as assessed by the trial administrator. DFS is defined as the time elapsed from randomization until tumor recurrence or death from any cause (whichever occurs earlier).

  • Test Drug

    Imfinzi® KEYTRUDA® OPDIVO Tecentriq® Zongertinib (BI 1810631)

Participate Sites
6Sites

Recruiting6Sites

2025-09-01 - 2035-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Tablets; Subcutaneous injections

Participate Sites
6Sites

Recruiting6Sites

2024-01-01 - 2040-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-01-01 - 2031-02-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-02-01 - 2024-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-08-01 - 2024-11-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2024-04-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2018-01-15 - 2029-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting4Sites

2021-12-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-02-06 - 2029-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB